<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1DA78802-0659-4398-B40B-7FA41B56BBF3"><gtr:id>1DA78802-0659-4398-B40B-7FA41B56BBF3</gtr:id><gtr:name>innovate UK</gtr:name><gtr:address><gtr:line1>North Star House North Star Avenue</gtr:line1><gtr:city>Swindon</gtr:city><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E48D56F-BC7F-48CF-B82B-6FBEBD4451B2"><gtr:id>1E48D56F-BC7F-48CF-B82B-6FBEBD4451B2</gtr:id><gtr:name>Brazilian Association of Amyotrophic Lateral Sclerosis (ABRELA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2"><gtr:id>F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2</gtr:id><gtr:name>University of Miami</gtr:name><gtr:address><gtr:line1>1204 Dickinson Drive</gtr:line1><gtr:line2>Rhodes House</gtr:line2><gtr:line3>Building 37-A</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D7DAB1AF-9A9E-4CB0-A291-CC8D83EF0FC4"><gtr:id>D7DAB1AF-9A9E-4CB0-A291-CC8D83EF0FC4</gtr:id><gtr:name>Instituto Paulo Gontijo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89567AAF-2DC2-44FC-9DC1-58C569EB26D2"><gtr:id>89567AAF-2DC2-44FC-9DC1-58C569EB26D2</gtr:id><gtr:name>Iron Horse Diagnostics, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BAF7118-A7CB-4385-903E-255DD6F6908A"><gtr:id>7BAF7118-A7CB-4385-903E-255DD6F6908A</gtr:id><gtr:name>Friedrich Schiller University Jena (FSU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1DA78802-0659-4398-B40B-7FA41B56BBF3"><gtr:id>1DA78802-0659-4398-B40B-7FA41B56BBF3</gtr:id><gtr:name>innovate UK</gtr:name><gtr:address><gtr:line1>North Star House North Star Avenue</gtr:line1><gtr:city>Swindon</gtr:city><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E48D56F-BC7F-48CF-B82B-6FBEBD4451B2"><gtr:id>1E48D56F-BC7F-48CF-B82B-6FBEBD4451B2</gtr:id><gtr:name>Brazilian Association of Amyotrophic Lateral Sclerosis (ABRELA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2"><gtr:id>F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2</gtr:id><gtr:name>University of Miami</gtr:name><gtr:address><gtr:line1>1204 Dickinson Drive</gtr:line1><gtr:line2>Rhodes House</gtr:line2><gtr:line3>Building 37-A</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D7DAB1AF-9A9E-4CB0-A291-CC8D83EF0FC4"><gtr:id>D7DAB1AF-9A9E-4CB0-A291-CC8D83EF0FC4</gtr:id><gtr:name>Instituto Paulo Gontijo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89567AAF-2DC2-44FC-9DC1-58C569EB26D2"><gtr:id>89567AAF-2DC2-44FC-9DC1-58C569EB26D2</gtr:id><gtr:name>Iron Horse Diagnostics, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BAF7118-A7CB-4385-903E-255DD6F6908A"><gtr:id>7BAF7118-A7CB-4385-903E-255DD6F6908A</gtr:id><gtr:name>Friedrich Schiller University Jena (FSU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CF74FEB1-A15E-4984-A768-008B70F12C51"><gtr:id>CF74FEB1-A15E-4984-A768-008B70F12C51</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Turner</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK01014X%2F1"><gtr:id>3C22CD6E-0DA5-4165-BC2A-A99E00E2DA14</gtr:id><gtr:title>Developing The Oxford Study for Biomarkers in Motor Neuron Disease (BioMOx): Capturing pre-symptomatic events and advancing clinical translation</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K01014X/1</gtr:grantReference><gtr:abstractText>Motor neuron disease (MND) is a neurodegenerative condition in which the upper and lower motor neurons of the brain and spinal cord die prematurely. Also known as amyotrophic lateral sclerosis (ALS), it leads to progressive muscle weakness and wasting affecting the arms, legs, and speech and swallowing muscles. Involvement of the motor nerves supplying the respiratory muscles leads to death within three years of the onset of symptoms for half of patients. There is no effective treatment despite multiple drug trials over the last 20 years. About 5000 people suffer from MND in the UK, and many more are indirectly affected as their carers. It affects men and women and, although the peak incidence is in the early 60s, there is a wide age range.

Little is understood about why people develop MND. Whilst for most patients there is no clear single genetic reason for developing the disease, in a small number of patients there are multiple family members at risk due to single mutations or expansions in the genetic code. This project will study healthy volunteers who are known to carry genetic abnormalities linked to the development of MND, in order to try and capture the very earliest signs of nerve damage. Such changes might reveal new targets for preventative drug therapy, that then also have value in slowing progress in those with established disease. This part of the project will use one of only two very strong magnetic field (7 Tesla) MRI scanners in the UK in order to detect subtle changes in brain function and structure. Developments in MRI mean that it is now possible to study the spinal cord as well as the brain, and to look non-invasively at chemical substances within the tissue using a technique known as Magnetic Resonance Spectroscopy. This will be coupled to an extremely sensitive magnetoencephalography (MEG) scanner, which can detect patterns of brain motor nerve activity in real-time. This unique combination has the potential to unlock previously unrecognised changes in the brain and spinal cord of individuals long before symptoms appear, with the aim of identifying new targets for therapy, and new ways to monitor future therapeutic agents.

The symptoms of MND may initially not seem serious to the GP. Once referred to a hospital physician, making a diagnosis is not always straightforward without a diagnostic test. Currently diagnosis depends upon the opinion of an experienced neurologist and the exclusion of potential mimic disorders, which often involves lengthy investigations and a distressing period of uncertainty for patients. On average MND patients wait at least one year for a diagnosis. This delays the earlier administration of the only marginally disease-slowing medication, riluzole, and might be one reason that so many other drug trials have failed to show benefit. It is also precious time when individuals wish to maximise the quality of their remaining life. Finding reliable markers of disease activity in MND, called biomarkers, might help to speed up diagnosis, aid care-planning, and the assessment of new candidate drugs.

The Oxford Study for Biomarkers in MND (BioMOx) is a group of more than 60 MND patients, of all sub-types, who volunteered to be followed throughout their disease, undergoing tests every six months to try and identify biomarkers. Advanced MRI brain scans and analysis of spinal fluid and blood have revealed several candidates, and shown that their combination improves accuracy. This project will test these in people whose symptoms make MND a likely diagnosis, and in people with disease mimics, in order to see which biomarkers perform most reliably. It will also allow BioMOx to continue studying new cases of MND at regular intervals in order to understand why the pattern and speed of spread of initially isolated symptoms varies between individuals. This might help with the more efficient organisation of clinical trials, as well as effective care-planning.</gtr:abstractText><gtr:technicalSummary>The aims of this project are:

1. To understand the earliest, pre-symptomatic changes in those carrying genetic mutations linked to MND, and how they link to spread of symptoms in affected individuals.

2. The refinement, validation and clinical translation of a multimodal biomarker diagnostic signature for MND.

The objectives of this project are:

1. The longitudinal study of pre-symptomatic individuals at risk of MND, particularly those carrying expansions of the C9ORF72 hexanucleotide repeat, as well as those with pathological SOD1, TARDBP and FUS gene mutations. It will uniquely combine the spatial resolution of very high-field 7 Tesla MRI of the brain and cord (including GABA and glutamate MR Spectroscopy, MRS), with the temporal resolution of cerebral magnetoencephalography (MEG) to explore changes in cortical neurophysiology that pre-date symptom onset, and with the hope of capturing the transition to disease in a small proportion of individuals. Incident MND cases will also be studied longitudinally in comparison.

2. To perform multivariate analysis of existing candidate neuroimaging, biofluid and eye-tracking biomarkers acquired through BioMOx, and to test performance in undiagnosed patients with focal weakness referred for electromyography and established mimics of MND ('disease controls') referred to me in the Oxford MND Centre.

The discovery that pre-symptomatic individuals have changes in brain function or structure compared to healthy individuals with no family history of MND profoundly influences the scientific thinking about this condition. As well as raising the possibility of preventative therapies for familial cases, there would be the hope of additional value when similar treatments are applied earlier to apparently sporadic cases. Such cases would be detected at an earlier stage through the development of a robust biomarker signature for MND, and the BioMOx resource offers a unique opportunity to develop this.</gtr:technicalSummary><gtr:potentialImpactText>Several groups will benefit from the research proposed:

1. Patients and carers

Biomarker research such as that proposed, aimed at improving the diagnostic pathway and prognostication, will improve patients' and carers' quality of life. MND patients frequently report that the delay in their diagnosis was distressing and deprived them of time to enjoy remaining life before the onset of severe disability. They resent the necessity for lengthy therapeutic trials that rely on survival as the principal outcome measure. This proposal's development of biomarkers sensitive to early response (or lack) would mark a major step in reducing clinical trial length and permit faster rejection of ineffective candidates. There is an enormous desire among MND patients and their carers to take part in clinical research, despite knowing that it may not directly benefit them. They recognise that this is a vital way to develop therapeutic options, and those facing the particular challenge of a family history of MND stand to gain from understanding the earliest changes. There may well be benefits for patients with other neurodegenerative disorders through the discovery of mechanisms translatable across diseases. 

2. Commercial sector

With common themes emerging in the pathogenesis of neurodegenerative disorders, such as protein misfolding, pharmaceutical companies are increasingly interested in MND as one that (regrettably) runs its course over a short time frame compared with Alzheimer's and Parkinson's disease. The need for validated biomarkers of disease activity has become the major obstacle which this research addresses. The development of the BioMOx framework for cohort studies in MND also provides valuable knowledge about natural history and stratification of patients for future trials Information on the earliest stages of disease development may help to maximise success of clinical trials in the longer term. Another area of gain for industry is in the 'repositioning' of their abandoned drug libraries, which depends critically on the biomarker development. The biotech industry also benefits through promotion and development of novel biomarker assays and diagnostic kits that may emerge from the work proposed.

3. Policy makers &amp;amp; funding agencies

Both benefit from greater understanding of MND patients' needs and concerns. I will continue to support the MND Association in lobbying Government about the high care burden of MND and the need for rapid access to support. I will continue to highlight the value of non-therapeutic clinical research as vital groundwork to therapeutic translation. The process of research ethics committee approval is currently prohibitive to all but large longitudinal studies, and frequently appears adversarial. This point was highlighted in my contribution to the 'National Strategy for MND' presented to Government, along with bureaucratic barriers around sharing of biofluid samples across international boundaries which is currently holding back wider collaborative possibilities.

4. UK economy and global science platform

In the longer-term the successful prevention or even just delay in the development of disability, for up to 10% of MND patients (the proportion with a genetic mutation identified at present), would substantially reduce loss of productive years for both patients and carers, and reduce the overall burden of long-term disability. The use of advanced brain scanning techniques, including one of only two UK 7 Tesla MRI scanners and MEG, towards the long-term goal of pre-symptomatic therapeutic intervention in this most challenging of diseases, provides a very strong example of the UK leading the way in cutting-edge research. This has the potential to encourage the brightest individuals to work in UK neuroscience, and supports wider efforts to make a scientific career attractive to those in full-time education.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-08-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1600088</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Engineering and Materials Science</gtr:department><gtr:description>AMBRoSIA</gtr:description><gtr:id>C3EEA9E6-45BA-46AF-B95A-D911231AA198</gtr:id><gtr:impact>SOPs for sample collection</gtr:impact><gtr:outcomeId>56d2d59f199652.29900202-1</gtr:outcomeId><gtr:partnerContribution>Harmonisation of, and multi-site collection of ALS neurochemical samples for biomarker discovery.</gtr:partnerContribution><gtr:piContribution>Application writing and expertise. Collection of ALS neurochemical samples for biomarker discovery.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Friedrich Schiller University Jena (FSU)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>NISALS</gtr:description><gtr:id>4B068542-DCE1-4759-A0DF-947A761665F3</gtr:id><gtr:impact>Consensus statementas on neuroimaging in ALS (Lancet Neurology 2011 and 2015).
Multi-site analysis of T1 and DTI data (paper on DTI 2016).
Paper on clinical correlations 2016</gtr:impact><gtr:outcomeId>QMPgxTnZyAg-1</gtr:outcomeId><gtr:partnerContribution>Online repository for multi-site MRI data for multi-site analyses.</gtr:partnerContribution><gtr:piContribution>Establishment of an international consortium of neuroscientists focused on neuroimaging in ALS.
Organise annual meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GENFI</gtr:description><gtr:id>7EE8C4F6-04A3-43D1-B370-71ADF203DEBA</gtr:id><gtr:impact>Harmonisation of data-collection</gtr:impact><gtr:outcomeId>56d2da8ea01124.13296376-1</gtr:outcomeId><gtr:partnerContribution>Multi-centre pooling of FTD data.</gtr:partnerContribution><gtr:piContribution>Provision of MRI and clinical data on FTD patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Innovate UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EPISWITCH</gtr:description><gtr:id>A148B8CD-8DCA-4534-9832-042DF19D8601</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>56d2e6e9358140.82771906-1</gtr:outcomeId><gtr:partnerContribution>Clinical research fellow funding</gtr:partnerContribution><gtr:piContribution>Provision of clinically-characterised blood samples from ALS patients and controls.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Miami</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>pre-FALS</gtr:description><gtr:id>5F67FAD2-FABA-4B71-AD78-1F87F6F0DABA</gtr:id><gtr:impact>Paper on DTI and R-FMRI 2016.
MEG beta band changes paper (HBM) 2016.</gtr:impact><gtr:outcomeId>rJKpPT5WZgF-1</gtr:outcomeId><gtr:partnerContribution>Provision of pre-counselled and pre-tested pre-symptomatic ALS genetic mutation carriers.</gtr:partnerContribution><gtr:piContribution>MEG and MRI study of pre-symptomatic carriers of ALS genetic mutations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Instituto Paulo Gontijo</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Brazilian ALS Associations</gtr:description><gtr:id>6EFD07F4-47E3-45DA-837B-1B88FE93CCF4</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>54638a9cba4a25.78234494-2</gtr:outcomeId><gtr:partnerContribution>Sharing of ideas. Platform for discussions. Plans for future joint grants.</gtr:partnerContribution><gtr:piContribution>Visit to share ideas about ALS care and research</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ulm</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Neurofilaments</gtr:description><gtr:id>D556188E-2132-48BC-8A59-8A3D7D7680A4</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-3</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Research Facilities</gtr:department><gtr:description>Neurofilaments</gtr:description><gtr:id>BC8C0111-0169-4ADB-A5CC-C0AE95CE899E</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-1</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AMBRoSIA</gtr:description><gtr:id>BAADBAE2-EB7C-4F47-A831-E109BB3830D9</gtr:id><gtr:impact>SOPs for sample collection</gtr:impact><gtr:outcomeId>56d2d59f199652.29900202-2</gtr:outcomeId><gtr:partnerContribution>Harmonisation of, and multi-site collection of ALS neurochemical samples for biomarker discovery.</gtr:partnerContribution><gtr:piContribution>Application writing and expertise. Collection of ALS neurochemical samples for biomarker discovery.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Exosomes in ALS</gtr:description><gtr:id>5E38AC02-46A3-47DB-AE07-31F5C5055C5D</gtr:id><gtr:impact>Paper on exosome analysis in ALS and PD;
DPhil student taken on to work on project;
High-impact review of EV biomarker field (Nature Reviews Neurology)
Methods paper in UFLC method for extraction (in submission)</gtr:impact><gtr:outcomeId>54638b7ee93321.13855107-1</gtr:outcomeId><gtr:partnerContribution>Techincal knowledge and expertise</gtr:partnerContribution><gtr:piContribution>Contribution of samples and post-doctoral time to develop exosomal assay for future ALS biomarker discovery;</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Centre for Human Brain Activity (OHBA)</gtr:department><gtr:description>MEG</gtr:description><gtr:id>0C5E202F-B05D-4E75-9113-1613E56F9E09</gtr:id><gtr:impact>Review paper on MEG 2014.
First-in-ALS paper on beta band changes (HBM 2016).</gtr:impact><gtr:outcomeId>XvDxkKuUevf-1</gtr:outcomeId><gtr:partnerContribution>Expertise and equipment, co-supervision of student.</gtr:partnerContribution><gtr:piContribution>Provision of DPhil student and supervision.
Integration with BioMOx ALS biomarker programme.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Primary Care Health Sciences</gtr:department><gtr:description>Hospital record linkage studies</gtr:description><gtr:id>1AE77E47-2EEB-4149-AC67-B7DDC362AE09</gtr:id><gtr:impact>Published studies in ALS relating to cancer 2010, head injury 2010 and cardiovascular fitness 2011, autoimmune disorders 2014, cerebrovascular injury 2015, psychiatric disorders 2016.
Published study in Huntington's relating to cancer 2013.</gtr:impact><gtr:outcomeId>iL5WamLWiPe-1</gtr:outcomeId><gtr:partnerContribution>Access to and statistical interrogation of Oxford and England Hospital Record Databases</gtr:partnerContribution><gtr:piContribution>Knowledge and hypothesis relating to ALS and neurological disease more widely</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Eye-tracking</gtr:description><gtr:id>84B5B207-03AC-48BA-9302-0D9E4260FA2F</gtr:id><gtr:impact>Data presented at international and patient-based meetings.
Review of field published in JAMA Neurology 2011. 
Paper in PLoS ONE on novel TMT using eye-tracker 2014.
Paper in ALS-FTD on longitudinal analysis in ALS 2015.</gtr:impact><gtr:outcomeId>ekWZcskTunG-1</gtr:outcomeId><gtr:partnerContribution>Expertise and equipment</gtr:partnerContribution><gtr:piContribution>DPhil student supervision. Expertise in ALS. Patients with ALS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>miRNAs in ALS</gtr:description><gtr:id>BEDF1B92-9640-4C82-B442-F35FF5AD7B08</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>56d2d62898bb28.62827139-1</gtr:outcomeId><gtr:partnerContribution>Technical expertise in miRNA analysis.</gtr:partnerContribution><gtr:piContribution>Intellectual contribution to grant application. Provision of clinically-characterised CSF and blood samples for miRNA biomarker discovery.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Exosomes in ALS</gtr:description><gtr:id>81AA43C7-F593-4358-A8E1-45A76E7799A9</gtr:id><gtr:impact>Paper on exosome analysis in ALS and PD;
DPhil student taken on to work on project;
High-impact review of EV biomarker field (Nature Reviews Neurology)
Methods paper in UFLC method for extraction (in submission)</gtr:impact><gtr:outcomeId>54638b7ee93321.13855107-2</gtr:outcomeId><gtr:partnerContribution>Techincal knowledge and expertise</gtr:partnerContribution><gtr:piContribution>Contribution of samples and post-doctoral time to develop exosomal assay for future ALS biomarker discovery;</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Centre for Functional MRI of the Brain (FMRIB)</gtr:department><gtr:description>Post mortem MRI</gtr:description><gtr:id>B11CDB31-6C3B-4CF2-8BAB-B66909E0C58B</gtr:id><gtr:impact>Development of tools for the cross-correlation of MRI and histopathological material.</gtr:impact><gtr:outcomeId>56d2d84ba3ec62.37493154-1</gtr:outcomeId><gtr:partnerContribution>PM MRI sequence development and histological correlation</gtr:partnerContribution><gtr:piContribution>Grant application and provision of clinically-characterised MRIs and post mortem tissue from BioMOx cohort.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swansea University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cholesterol metabolomics</gtr:description><gtr:id>F109DE73-F58E-43CF-B971-A4EF049EB101</gtr:id><gtr:impact>Paper published 2016.</gtr:impact><gtr:outcomeId>UfHh5uSo5Ef-1</gtr:outcomeId><gtr:partnerContribution>Cholesterol metabolite analysis as potential biomarkers.</gtr:partnerContribution><gtr:piContribution>Provision of serum and CSF from ALS patients and healthy controls.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brazilian Association of Amyotrophic Lateral Sclerosis (ABRELA)</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Brazilian ALS Associations</gtr:description><gtr:id>1C739BB7-E233-457C-9CDD-C01EA60306F0</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>54638a9cba4a25.78234494-1</gtr:outcomeId><gtr:partnerContribution>Sharing of ideas. Platform for discussions. Plans for future joint grants.</gtr:partnerContribution><gtr:piContribution>Visit to share ideas about ALS care and research</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Iron Horse Diagnostics, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Neurofilaments</gtr:description><gtr:id>34FEE2F8-513B-43B0-9C15-23D1DF4989F6</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-2</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ACE Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0E1EAB1A-C8A2-45E4-B860-22BFFF338624</gtr:id><gtr:impact>Organised workshop to consider Athleticism, Cardiovascular risk and Exercise in ALS patients.

Planned studies by attendees</gtr:impact><gtr:outcomeId>5463a697369ee4.89009580</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brazilian ALS Outreach</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E4FB0B97-2E83-4858-AD27-354ADCFEF6F5</gtr:id><gtr:impact>Invited presentations to ALS neurologists and researchers in Brazil (Sao Paulo and Curitiba)

New collaborations planned, and advice on setting up infrastructure for ALS care and research in Brazil.</gtr:impact><gtr:outcomeId>5463accd067641.33108410</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Geriatrics Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9B568A54-883E-419B-A062-4A100A6F67A5</gtr:id><gtr:impact>Update on MND care and research</gtr:impact><gtr:outcomeId>58bc435b47a755.55866097</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Legacy Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8B1FACF0-5FAB-4713-BAAF-1C5CF884A1BF</gtr:id><gtr:impact>Outline of Oxford MND Centre care and research</gtr:impact><gtr:outcomeId>58bc4488b44185.08368853</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Donor dinner</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0AE2AD82-70AD-45B6-A7F3-B6B079B4C26D</gtr:id><gtr:impact>Research presentations and discussion with patients and MNDA donors</gtr:impact><gtr:outcomeId>58bc462062fe45.21581101</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FTD UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E4A4E31A-00C4-4EF9-9E83-E043CA4F0FA0</gtr:id><gtr:impact>Presentation on CSF biomarkers in ALS.</gtr:impact><gtr:outcomeId>56d2eaa8174c78.84500687</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ftduk.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Major donor presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B45A57C5-FBD8-45CC-9895-336772B3CEF7</gtr:id><gtr:impact>Annual MND Association-organised Royal Society presentation of my ALS research to major donors.
Visits to Oxford MND Care &amp;amp; Research Centre - tour of labs 2012, 2013.
Lady Edith Wolfson Day at Sheffield 2013.

Interest in continued funding of ALS research.</gtr:impact><gtr:outcomeId>owf7zHv2qpR</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pre-NI</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>82094A82-67D0-4327-B4A9-20F6FC6618AD</gtr:id><gtr:impact>Workshop on pre-symptomatic studies in neurodegeneration.</gtr:impact><gtr:outcomeId>56d2e65d188e74.46163203</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>King's MSc Neuroscience</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>02D2F381-53C8-4E54-AF4E-985C808471E6</gtr:id><gtr:impact>Reviewed marking scheme and course material.

Educational value in understanding how MSc courses run in other institutions</gtr:impact><gtr:outcomeId>fagP1kGGvJs</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>King's Neuroscience / MND seminar</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>63B0F740-4492-4A45-B0B7-DF95F506DAA6</gtr:id><gtr:impact>Invited talk on 'New frontiers in ALS research'.
Invited debate on role of tracheostomy in ALS.

Raised personal research profile.</gtr:impact><gtr:outcomeId>kYhzVmoPqGm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuraltus Pharmaceuticals</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B981CD5A-9E67-4EC9-BA9C-84316A23E704</gtr:id><gtr:impact>Expert advice on unmet clinical needs of ALS patients.</gtr:impact><gtr:outcomeId>56d2e77ac61780.08345398</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cytokinetics Tirasemtiv trial</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>41F3CCD1-7F2F-49CC-BB41-4821E868EAA3</gtr:id><gtr:impact>Enrollment of participants in Phase IIb study.

Enhancement of Oxford's status as clinical trials centre in ALS.
Increased recruitment to clinical research more widely.</gtr:impact><gtr:outcomeId>HDXirV31Rid</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh Advanced Neurology Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23F26577-B177-4C20-8A33-C0C474C29BDF</gtr:id><gtr:impact>Invited discussant for clinicopathological conference concerning rare case of ALS.
Other talks on clinical neurological topics more widely.

Increased profile as ALS opinion leader.
CPD in general neurology</gtr:impact><gtr:outcomeId>qAVjrkxa4At</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Taubman Institute Lectureship</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B061564F-E726-43BD-A41C-C639864FFBE1</gtr:id><gtr:impact>Invited presentation on ALS biomarkers

Stimulate local research and advice on logistics.</gtr:impact><gtr:outcomeId>5463a79d21f1c6.80177765</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School in Cognitive Neuroscience</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>99621ABC-898D-411E-A35F-C91638E8596E</gtr:id><gtr:impact>Talk on brain in ALS and FTD.</gtr:impact><gtr:outcomeId>56d2eb00e30be1.18742300</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Palliative Care Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>550EFD3E-B701-43BA-9F8E-0236264CAC8F</gtr:id><gtr:impact>Invited lecture on 'Palliative Care issues in MND' to 150 Palliative Care professionals.

Interest and awareness of MND-related issues.</gtr:impact><gtr:outcomeId>bMQdWhHq3iR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCP Advanced Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B3CAD34-1DCC-48C2-A472-B4811F1A2AC9</gtr:id><gtr:impact>Goulstonian Lecture on ALS biomarkers.</gtr:impact><gtr:outcomeId>56d2ec714a21e5.40409456</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSM Regional Study Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F0253093-0E8D-4867-A32B-A8FB2FE3B4EC</gtr:id><gtr:impact>Update on MND diagnosis.</gtr:impact><gtr:outcomeId>56d2e7c85f9dc0.33777732</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Legacy Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B89B5D6F-EE72-4EED-A017-F9B28520F8A7</gtr:id><gtr:impact>Overview of Oxford MND Clinic and research activities</gtr:impact><gtr:outcomeId>58bc41daa09803.32264416</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Neuroscience Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>131C272D-1703-4E3C-BEC2-57C7CA17DE2D</gtr:id><gtr:impact>Talk on Biomarkers in ALS</gtr:impact><gtr:outcomeId>56d2e56a905310.92246721</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Care Centre Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>04AE9F69-CBA5-4042-BE2D-5A2C592C7BA0</gtr:id><gtr:impact>Annual meeting of care centre directors, co-directors and coordinators to review best practice and future intiatives.</gtr:impact><gtr:outcomeId>56d2e957e37498.05777157</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Motor system workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8B8D9934-E16B-4AAE-B338-332FB2B1E13E</gtr:id><gtr:impact>Inter-disciplinary workshop to look at collaboration in study of motor system in health and disease</gtr:impact><gtr:outcomeId>58bc454fb357d9.42619242</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spanish Society of Neurology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E6828919-AFF6-4184-A7AA-16D8D9F83913</gtr:id><gtr:impact>Presentation of biomarker work

Advice sought from me on setting up similar research</gtr:impact><gtr:outcomeId>5463a5c16b6b45.14950767</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>JNNP Editorial Board</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>839E161B-83D1-4BB9-9FCE-6C6FDEA567A3</gtr:id><gtr:impact>Commissioning Editor and Editorial Board member for JNNP.</gtr:impact><gtr:outcomeId>56d2e413de0272.06827221</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.jnnp.com</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRC-D PET</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AE249C60-C8BF-4F9A-BAE1-D356A99A3152</gtr:id><gtr:impact>Workshop on application of new PET tracers to neurodegenerative disorders</gtr:impact><gtr:outcomeId>56d2e81500e381.97061914</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ABN Clinical Research Advisory Committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6DE9C882-E7AE-4BA7-8B4A-F1A82ACA6408</gtr:id><gtr:impact>Discussion of ABN strategy and funding for clinical research in neurology.

Raised personal profile and chance to shape future research agenda.</gtr:impact><gtr:outcomeId>it46JHKZCmL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SENA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3F453DF7-6F52-4B2C-9E5D-943CB64127B1</gtr:id><gtr:impact>Presentation on latest research and management in ALS to neurologists</gtr:impact><gtr:outcomeId>56d2e378427775.08248278</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ulm Neuroscience Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>927D1061-6134-41C5-95ED-CC4F6DD8234E</gtr:id><gtr:impact>Presentation on ALS biomarkers.</gtr:impact><gtr:outcomeId>56d2e8b9c0ea29.70593104</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICCN meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1482A30E-2EBC-4B3F-A3F0-B1BC8CE716BA</gtr:id><gtr:impact>Invited presentation on neuroimaging biomarkers in ALS

Increased awareness and profile-raising</gtr:impact><gtr:outcomeId>5463a711ec9804.36749811</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>P-CNS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0E5AD971-98DB-4733-9E52-D96266373BF2</gtr:id><gtr:impact>Day workshop to educate GPs about neurological symptoms</gtr:impact><gtr:outcomeId>56d2e2d195a661.36237524</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.p-cns.org.uk</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PLS Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>498B5487-34CB-4E1D-A404-85BE513126BF</gtr:id><gtr:impact>1st UK event for sufferers with Primary Lateral Sclerosis, a rare form of MND. Opportunity for patients and carers to hear latest understanding of this condition and research.</gtr:impact><gtr:outcomeId>56d2dcb727eeb2.61458367</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ALSRG</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E6C56F8F-590A-4429-996A-D85DED6DE54F</gtr:id><gtr:impact>Discussions around clinical trials and funding for ALS research

Planned meeting to redesign clinical trials in ALS</gtr:impact><gtr:outcomeId>5463a95608b476.09432747</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK FTD meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>116ADA7D-139D-4A74-82E4-3B83B122C851</gtr:id><gtr:impact>Update on latest research and overlap with MND.</gtr:impact><gtr:outcomeId>58bc45b169fa31.68922542</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Omnia-Med Study Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>154AD254-1267-4A00-8422-72F9D3EBCEA6</gtr:id><gtr:impact>Talk on MND diagnosis and management.</gtr:impact><gtr:outcomeId>56d2ebcf43da46.02018055</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Asia-Pacific FTD-MND</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9FDF633B-AE46-4203-9051-353CBB4AA9D2</gtr:id><gtr:impact>Talks on the cerebral lesion in ALS and how I manage ALS.</gtr:impact><gtr:outcomeId>56d2eb5ecbb047.60652001</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>www.oxfordmnd.net</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4ED94F44-C231-4BFD-AC77-14EC5CF1D1B3</gtr:id><gtr:impact>Development and maintenance of website for Oxford MND Centre.

Increased awareness of Centre's activity, information for patients about Care &amp;amp; Research.</gtr:impact><gtr:outcomeId>E2EE66F82C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.oxfordmnd.net</gtr:url><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biogen Idec Imaging Advisory Panel</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>341D04BF-EC68-4E47-B526-4FC6862703C5</gtr:id><gtr:impact>Expert view on use of neuroimaging for ALS biomarkers

Company keen to pursue</gtr:impact><gtr:outcomeId>5463a8f57f10b1.12114284</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ontario Brain Institute</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3C9753AA-8F3F-4E48-AACD-5EC636AFE2D8</gtr:id><gtr:impact>Invited to review 5-year programme and make recommendations for improvement.

Increased awareness of other international studies and personal profile-raising as opinion leader in field.</gtr:impact><gtr:outcomeId>DC7Xxu1G9GD</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ondri.ca</gtr:url><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Biomedical Research Advisory Panel</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C21845AB-4582-4808-9704-DA5E02D6B11C</gtr:id><gtr:impact>Discussion and scoring of grant applications

Helping to shape national MND research</gtr:impact><gtr:outcomeId>rer6mLPGY1v</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.mndassociation.org</gtr:url><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GP Study Day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>772C7354-4AFA-44EC-8057-B2EE74B075FA</gtr:id><gtr:impact>Educational day for GPs on neurology including MND</gtr:impact><gtr:outcomeId>58bc42e7b3b5b6.54786593</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA regional patient meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6FF67447-3F10-428A-B7D7-23BAC622D4CC</gtr:id><gtr:impact>Annual regional branch meetings to 25-50 patient and carer attendees. Presented biomarker research progress.

2011 Oxfordshire branch
2011 National Spring Conference (Cambridge)
2012 Cambridgeshire branch
2013 Oxford, Gloucester &amp;amp; Reading West branches
2013 Reading
2015 Oxfordshire

Improved awareness and hope for patients and carers.
Offers to participate in research.</gtr:impact><gtr:outcomeId>eKb58QHBRa3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2011,2012,2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gloucester Branch MNDA talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D96CE734-32F0-48E4-8E01-F3250F3F82A1</gtr:id><gtr:impact>Research update</gtr:impact><gtr:outcomeId>58bc41886bd379.62879657</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CSF Society</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>84B76643-5572-4ECD-8CB1-132B65A399A7</gtr:id><gtr:impact>Collaboration and standardisation on all aspects of CSF analysis</gtr:impact><gtr:outcomeId>58bc427c8282c6.09083076</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCN</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>050B4DB3-652D-4FFF-A812-61AF01ADE44C</gtr:id><gtr:impact>Royal College of Nursing presentation on History of MND.</gtr:impact><gtr:outcomeId>56d2ef42830098.34960421</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA small grants</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>MSD Reader</gtr:fundingRef><gtr:id>DC27FDB6-1296-453C-BCAD-C7741761868D</gtr:id><gtr:outcomeId>56d2cfab6f62e2.08408830</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>134391</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT CRTF Malcolm Proudfoot</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>07E4D05A-50AE-4EF4-B21E-8224B5865838</gtr:id><gtr:outcomeId>56d2d772725344.36846679</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>BRC Biomarker Theme</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>Biomarker theme</gtr:fundingRef><gtr:id>879E4325-0B81-45A9-95B0-AEB2DC654323</gtr:id><gtr:outcomeId>RXaeJLk1uKU</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA small grants</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>Athleticism in ALS meeting</gtr:fundingRef><gtr:id>255358E7-D1FD-4206-BBDB-35083C232992</gtr:id><gtr:outcomeId>54639ebdb60887.43830139</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA small grants</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>PLS Day</gtr:fundingRef><gtr:id>91F517B7-2C43-4BAB-8EA6-C50938318B40</gtr:id><gtr:outcomeId>56d2cebde35470.18875024</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain PhD Entry Fellowship Malcolm Proudfoot</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Guarantors of Brain</gtr:fundingOrg><gtr:id>BB95DE9B-DB3E-4F5E-8750-FFECCC3064F3</gtr:id><gtr:outcomeId>PtXcmBhPLQF</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Families for the Treatment of Hereditary MND (FaTHoM) study day</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>3A4CF746-EDAA-48C9-9E7F-BCE1125C3376</gtr:id><gtr:outcomeId>58bc3f784ee4d6.34099575</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>54976</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>John Fell Fund</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>564408F1-D481-44DA-83CB-B9376C83B793</gtr:id><gtr:outcomeId>56d2ce09e34a32.24456447</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100100</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Thierry Latran Foundation 4th Project Call</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Thierry Latran Foundation</gtr:fundingOrg><gtr:fundingRef>PROMISES</gtr:fundingRef><gtr:id>FBA6B2C4-D390-4F72-9315-640038DACDC1</gtr:id><gtr:outcomeId>JHEPLs1LFHz</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ice Bucket Challenge</gtr:description><gtr:end>2021-04-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>AMBRoSIA</gtr:fundingRef><gtr:id>AB08F4EA-380A-4627-A7DB-D2CE015BAA15</gtr:id><gtr:outcomeId>56d2ce4dda57f6.42320927</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>The Neuroimaging Symposium in Amyotrophic lateral sclerosis (ALS) (NISALS)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B18CCACE-54F8-4CFB-8564-96A5DC9C9E78</gtr:id><gtr:impact>I convened the first meeting in 2010, now annual, of global researchers studying ALS using neuroimaging. Guidelines were developed and published in Lancet Neurology PMID:21511189. Second meeting in Jena Germany 2011 has laid foundation for standardization and harmonization of MRI data across centres. Meeting in Miami developing multi-centre collaborative MRI study. Meetings in Milan, Leuven, Orlando and Dublin have developed multi-centre projects and Governance framework.</gtr:impact><gtr:outcomeId>PTWjRE1fi33</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21511189</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NHS Direct patient information on MND</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>185A219A-627E-4821-9D7C-1C4206486770</gtr:id><gtr:impact>Re-wrote and updated the NHS Direct patient information on MND.</gtr:impact><gtr:outcomeId>5463b655e21cd4.28219418</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://www.nhs.uk/conditions/Motor-neurone-disease/Pages/Introduction.aspx</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIV withdrawal UK guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>30095826-E2DA-4F95-9CB0-838BF8A4C707</gtr:id><gtr:impact>Audit and guideline development for the withdrawal of NIV in ALS patients.</gtr:impact><gtr:outcomeId>56d2e02f3aa187.39773065</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>CSF NFL as a diagnostic, predictive and pharmacodynamic biomarker in ALS</gtr:description><gtr:id>A906FD10-9116-4BC0-ACE5-F6B404F531FC</gtr:id><gtr:impact>International workshop planned for harmonisation of efforts.</gtr:impact><gtr:outcomeId>56d2ed9580e451.19378052</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>NFL</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A Multi-centre Biomarker Resource Strategy in ALS. Oxford, QMUL and Sheffield collecting and storing biofluid samples from 300 patients and 450 controls over 5 years (MNDA-funded).</gtr:description><gtr:id>1628F6C9-9B91-475D-8C65-404F6568DEB0</gtr:id><gtr:impact>Infrastructure and governance nearing completion prior to first recruitment April 2017.</gtr:impact><gtr:outcomeId>58bc4f6dc01581.20514383</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AMBRoSIA</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Ethical approval to seek consent for extra sample of CSF and blood from patients having routine investigations, to use as disease controls in biomarker studies.</gtr:description><gtr:id>585E1805-78C8-4F1E-A8A2-BDA8C19B63AE</gtr:id><gtr:impact>Access to disease controls for ALS biomarker development, including contribution to standardisation efforts.
New collaborations with local groups increases sample collecting infrastructure.</gtr:impact><gtr:outcomeId>5463b7ae9492b4.66224218</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Oxford Biomarker Bank</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Longitudinal MRI, CSF and blood from large group of ALS patients</gtr:description><gtr:id>50D07174-F251-4D1C-A916-B0C3DAAC8AD5</gtr:id><gtr:impact>Candidate MRI and biofluid biomarkers.
Major finding of NfL as a prognostic biomarker through sample sharing with QMUL</gtr:impact><gtr:outcomeId>AC2wsjcu16C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ALS biomarkers</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>UFLC method offers greater yield than conventional UC from CSF.</gtr:description><gtr:id>26BB99F7-7DA5-48E7-B397-460243DCD0A0</gtr:id><gtr:impact>Methods paper in preparation</gtr:impact><gtr:outcomeId>58bc4eb9c9bd78.19571685</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EV extraction from CSF</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BB9CC518-02AA-44E9-B1B7-F549DA4DADC7</gtr:id><gtr:title>Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c0ee7b319752e06e1099570139e53bb"><gtr:id>4c0ee7b319752e06e1099570139e53bb</gtr:id><gtr:otherNames>B?umer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54637a564551b8.57087489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD71A6F5-E774-4DE3-B14E-4D9B84E4807B</gtr:id><gtr:title>A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0820ba371c3d623629717b3bc9288d69"><gtr:id>0820ba371c3d623629717b3bc9288d69</gtr:id><gtr:otherNames>McGeachan AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58bc2d23b11060.50246747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D9A8111-7E61-4B6F-B6BF-B2A8358EFE98</gtr:id><gtr:title>Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a439e3cead6e102b8a7c8e439170b4fb"><gtr:id>a439e3cead6e102b8a7c8e439170b4fb</gtr:id><gtr:otherNames>Wei W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>58bc2d21c14367.95510829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>720EBB9C-3F0B-4EE1-9E3F-56CD588EA337</gtr:id><gtr:title>Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) in the older adult.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41fbbad9f0a6954389ba269e1ef9be19"><gtr:id>41fbbad9f0a6954389ba269e1ef9be19</gtr:id><gtr:otherNames>Aurangzeb S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>56d2c61da57eb9.26522156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3685A68A-D0EE-4362-8EED-EDB867DCAF54</gtr:id><gtr:title>Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade-off?</gtr:title><gtr:parentPublicationTitle>Clinical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9163</gtr:issn><gtr:outcomeId>pm_12643_23_23017147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>555E84C5-2EF9-4157-A866-4005173BDC9F</gtr:id><gtr:title>NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa8dc20d96363a2f4e574a132c76feaf"><gtr:id>aa8dc20d96363a2f4e574a132c76feaf</gtr:id><gtr:otherNames>Kenna KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58bc2d23ef0489.56536870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9B67270-4A16-479F-B9AA-013941786DA1</gtr:id><gtr:title>Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?</gtr:title><gtr:parentPublicationTitle>Alzheimer's research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ea7cb7c5b66d2c17f42873f65f06866"><gtr:id>1ea7cb7c5b66d2c17f42873f65f06866</gtr:id><gtr:otherNames>Merlo Pich E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d2c61e39c0e6.29393236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39F1CAA0-211B-46E1-A5D6-B68A6B2BB41F</gtr:id><gtr:title>Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba2675f7257ca9d3f840f3c2abd04605"><gtr:id>ba2675f7257ca9d3f840f3c2abd04605</gtr:id><gtr:otherNames>Rutter-Locher Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58bc2d2497ee22.11457554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AD92E70-38C2-4126-8A63-1963A72D664F</gtr:id><gtr:title>DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29b86ddd0f7ed15df4951ce2afd4de30"><gtr:id>29b86ddd0f7ed15df4951ce2afd4de30</gtr:id><gtr:otherNames>McDermott CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>58bc2d244a2668.76377550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14C40CC5-CAED-4143-A698-F9C91A71EA81</gtr:id><gtr:title>The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61c454b22.82308619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AD6E2FC-20D4-48A8-8981-F8863EE9B5C2</gtr:id><gtr:title>Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb87f110bb4914af0973f4d8272af1b6"><gtr:id>bb87f110bb4914af0973f4d8272af1b6</gtr:id><gtr:otherNames>Balendra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>54637a56e7ea46.94884414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA08F4EF-0D5D-4C1E-9F95-B994ECCD0B58</gtr:id><gtr:title>Controversies and priorities in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12643_23_23415570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7078A2B8-7DF4-4F56-A003-93B772C425F0</gtr:id><gtr:title>Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda758646dc6e6fea4163230f74012c1"><gtr:id>cda758646dc6e6fea4163230f74012c1</gtr:id><gtr:otherNames>UKMND-LiCALS Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12643_23_23453347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B784CF5-E0BF-47FB-A6BC-D1AEAB1C406F</gtr:id><gtr:title>Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>54637a571b8d83.39446226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BADDA698-485B-46E5-8BE4-F3C63175BFEB</gtr:id><gtr:title>Myelin imaging in amyotrophic and primary lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/101bf71c975bd01cb8c440f2b356903e"><gtr:id>101bf71c975bd01cb8c440f2b356903e</gtr:id><gtr:otherNames>Kolind S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42CFFF31-C3A4-4D6F-A2E9-A1E990F74595</gtr:id><gtr:title>Seasonal variation in Guillain-Barr&amp;eacute; syndrome: a systematic review, meta-analysis and Oxfordshire cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf1d3e43ee3bb582b85010320bd96245"><gtr:id>bf1d3e43ee3bb582b85010320bd96245</gtr:id><gtr:otherNames>Webb AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61b33a813.25952917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D0AD0E6-FC47-41F0-BC1C-B56D921DB699</gtr:id><gtr:title>The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61c760fe4.51837250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A937D83B-672A-4C86-99BE-82A1850BCF64</gtr:id><gtr:title>An eye-tracking version of the trail-making test.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebd4f8ec0d8b4f458086eedf1b434953"><gtr:id>ebd4f8ec0d8b4f458086eedf1b434953</gtr:id><gtr:otherNames>Hicks SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54637a566cb172.32338605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAAC260B-B662-4AC9-AC79-758DD2084630</gtr:id><gtr:title>Preface to 'Neuromythology'.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>58bc2d24e173a2.04910085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C4B7A09-61BC-4FFA-80FA-F9E3A98BA5AD</gtr:id><gtr:title>Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/014f62366555b270d7daae3cc0c9f4da"><gtr:id>014f62366555b270d7daae3cc0c9f4da</gtr:id><gtr:otherNames>Keogh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>58bc2d22ab2a13.62413449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C68F82A8-D64F-48BA-B1A8-9BA058E1401E</gtr:id><gtr:title>Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d804af8bcf32af37ab3754538291612"><gtr:id>3d804af8bcf32af37ab3754538291612</gtr:id><gtr:otherNames>Eisen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1388-2457</gtr:issn><gtr:outcomeId>56d2c61bd299f6.00587234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76B44DF4-DEBB-473E-A59B-14DE0F963FEC</gtr:id><gtr:title>Sweet food preference in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>58bc2d225b3a16.17665282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF69BBB5-B26D-4155-AA8E-8AC4EC0383A7</gtr:id><gtr:title>Defective cholesterol metabolism in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/431a767937725fdd7cabdb422318cce0"><gtr:id>431a767937725fdd7cabdb422318cce0</gtr:id><gtr:otherNames>Abdel-Khalik J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>58bc2d23252698.77004357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1EE83A5-C2A3-4444-9972-9B006D388545</gtr:id><gtr:title>Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ae2050cbea18d815e6670d53dc3ac5"><gtr:id>25ae2050cbea18d815e6670d53dc3ac5</gtr:id><gtr:otherNames>Strong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58bc2d227db7b9.60754493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>450EA739-79C1-4683-8360-950E2FF95867</gtr:id><gtr:title>The wisdom of neurologists.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>56d2c61e6b1eb4.69683210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC7B80D4-DE68-4A4A-9C61-2FE46160EDF3</gtr:id><gtr:title>Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2deb3bad43536c8c939526c0265dbb29"><gtr:id>2deb3bad43536c8c939526c0265dbb29</gtr:id><gtr:otherNames>Filippi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56d2c61b5f1623.80484490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62905AAB-58F4-46A7-8DD5-FBE796030D9E</gtr:id><gtr:title>Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>54637a57e4a135.06339835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F7C1E29-4491-4DCB-BEB7-C8E4FFE7B065</gtr:id><gtr:title>Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis.</gtr:title><gtr:parentPublicationTitle>Academic radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12694b6fc260157c5202509072982484"><gtr:id>12694b6fc260157c5202509072982484</gtr:id><gtr:otherNames>Foerster BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1076-6332</gtr:issn><gtr:outcomeId>pm_12643_23_23931423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C665EBE-FB9F-41F6-92A6-7D8B4EA75005</gtr:id><gtr:title>Promoting clinical and patient-oriented research to identify the pathogenesis of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a6684e12293eedd4c487bdc6661723f"><gtr:id>7a6684e12293eedd4c487bdc6661723f</gtr:id><gtr:otherNames>Mitsumoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E734AFD0-BA1C-4CD4-A4BD-2CB6F2C7144C</gtr:id><gtr:title>Unmasking of incipient amyotrophic lateral sclerosis by botulinum toxin therapy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4764aa823b7a020b3590bce2cc799303"><gtr:id>4764aa823b7a020b3590bce2cc799303</gtr:id><gtr:otherNames>Kent L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12643_23_23400499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>824171F5-2008-48A5-8B24-A4FC583B6595</gtr:id><gtr:title>Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>585d331eb2bad3.57861754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99CB107E-3604-4E9C-AD13-85FC33E00B0D</gtr:id><gtr:title>Management of sialorrhoea in motor neuron disease: a survey of current UK practice.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302838d299ec84da92f209d22fc4b287"><gtr:id>302838d299ec84da92f209d22fc4b287</gtr:id><gtr:otherNames>Hobson EV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23647474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46254587-B879-4FF7-94B1-18EC88A1045D</gtr:id><gtr:title>An elusive cause for a progressive neuropathy.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41fbbad9f0a6954389ba269e1ef9be19"><gtr:id>41fbbad9f0a6954389ba269e1ef9be19</gtr:id><gtr:otherNames>Aurangzeb S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>56d2c61e0c2952.48443595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>556D4604-7425-4DE1-B578-19A48F607309</gtr:id><gtr:title>Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d804af8bcf32af37ab3754538291612"><gtr:id>3d804af8bcf32af37ab3754538291612</gtr:id><gtr:otherNames>Eisen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23879681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A9B1EE9-4C0F-40AF-8EE1-356A377F4875</gtr:id><gtr:title>Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3251657938f8056db79b6c1e54c6ed66"><gtr:id>3251657938f8056db79b6c1e54c6ed66</gtr:id><gtr:otherNames>ProGas Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>58bc2e0ac3ab51.29970730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>899692BA-3489-4154-911C-37A5C6D9950E</gtr:id><gtr:title>Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe424690789fe3b498adf4ad55c8999b"><gtr:id>fe424690789fe3b498adf4ad55c8999b</gtr:id><gtr:otherNames>Lu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5675e3a58a574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF9163AE-965B-4543-A2F9-A7A681BB586E</gtr:id><gtr:title>The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>NeuroImage. Clinical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b5a7d42b2114523fcf1688d21c532d0"><gtr:id>1b5a7d42b2114523fcf1688d21c532d0</gtr:id><gtr:otherNames>Menke RAL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2213-1582</gtr:issn><gtr:outcomeId>5a6f2d2b5ca691.07768545</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05163E61-34D9-4B39-AB72-2BDCF61D3EB3</gtr:id><gtr:title>The tough body at the epicentre of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>58bc2d22d216e7.42660792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D8114B1-EC27-49C2-AA83-E0D0483DB919</gtr:id><gtr:title>Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a31927906cffc4c4cbf31a0c8fd63195"><gtr:id>a31927906cffc4c4cbf31a0c8fd63195</gtr:id><gtr:otherNames>Thompson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>58bc2d24bc2a36.33699497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15CAA75E-7AA6-46E3-8319-95FABB8F57DF</gtr:id><gtr:title>Quantifying disease progression in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1039732cd08f0b19b673004518ad2ad4"><gtr:id>1039732cd08f0b19b673004518ad2ad4</gtr:id><gtr:otherNames>Simon NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>54637a57b7d835.14138573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19D680B5-1DDE-478A-97E8-AF41F7D2BA7C</gtr:id><gtr:title>Imaging in Neurodegenerative Disorders</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:isbn>978-0-19-967161-8</gtr:isbn><gtr:outcomeId>5463946574c954.20027718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>007425CF-61CF-4494-8B62-1CD8723171A2</gtr:id><gtr:title>Romberg's test no longer stands up.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>58bc2d250af397.67108027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6280DB4-CC9A-48C3-8155-FE17169969F9</gtr:id><gtr:title>Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac23f0115c5aab1cd4bb547272d0a65e"><gtr:id>ac23f0115c5aab1cd4bb547272d0a65e</gtr:id><gtr:otherNames>Fekete T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54637a569be7d9.38186887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CC78168-3F4E-4F4E-AE47-AE0A35E661E1</gtr:id><gtr:title>Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922738046572c98b4498b0faf60a5115"><gtr:id>922738046572c98b4498b0faf60a5115</gtr:id><gtr:otherNames>van der Kleij LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d2c61d4f7680.55374613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02F36A56-7324-4AF3-B594-135FB043E4BA</gtr:id><gtr:title>Tools and talk: an evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d804af8bcf32af37ab3754538291612"><gtr:id>3d804af8bcf32af37ab3754538291612</gtr:id><gtr:otherNames>Eisen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>54637a55a52de0.50147753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>821C2ED0-3AA8-4C55-A91A-A8660D1E573B</gtr:id><gtr:title>Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12643_23_23946298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BBF4A94-84F5-4253-97B7-05E8367F8260</gtr:id><gtr:title>Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54637a5768bb70.81114586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7033029F-0C09-460B-9BDF-5BF20B624E9F</gtr:id><gtr:title>Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d03ffb9b885afe6a58631746bc84369"><gtr:id>1d03ffb9b885afe6a58631746bc84369</gtr:id><gtr:otherNames>Proudfoot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn><gtr:outcomeId>58bc2d236e0bf0.59481580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16946607-E7F1-4934-A83C-B3E9B8F7D087</gtr:id><gtr:title>Spread of pedigree versus genetic ancestry in spatially distributed populations.</gtr:title><gtr:parentPublicationTitle>Theoretical population biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c63964e4077a3d288c00e625613d207"><gtr:id>9c63964e4077a3d288c00e625613d207</gtr:id><gtr:otherNames>Kelleher J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-5809</gtr:issn><gtr:outcomeId>56cc3a809f2735.76436086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B86F9063-89AA-4AD7-96E6-53383F26735E</gtr:id><gtr:title>Mechanisms, models and biomarkers in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87FE3F65-322F-4E06-BAA8-85C0E97AD8F9</gtr:id><gtr:title>Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a31927906cffc4c4cbf31a0c8fd63195"><gtr:id>a31927906cffc4c4cbf31a0c8fd63195</gtr:id><gtr:otherNames>Thompson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>5a6f2e37efb160.81041098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F096BEB-CD8F-4663-9F55-BA4F878CC1B0</gtr:id><gtr:title>A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ed1262063e9329e3175cc70758d0fa"><gtr:id>77ed1262063e9329e3175cc70758d0fa</gtr:id><gtr:otherNames>Dickens AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54638d6e38d3f9.33529791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83F906D0-B83C-42CA-AEBC-F3E261941D4F</gtr:id><gtr:title>Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d03ffb9b885afe6a58631746bc84369"><gtr:id>1d03ffb9b885afe6a58631746bc84369</gtr:id><gtr:otherNames>Proudfoot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d2c61cd0b7b4.77451711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE758486-448A-47FC-9C08-43247376DC82</gtr:id><gtr:title>Mimics and chameleons in motor neurone disease.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_12643_23_23616620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A09A910-640E-4E56-A327-27898792F9B0</gtr:id><gtr:title>Progressive dysphagia without dysarthria.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44b2b5a25623eebfaee8f1247a7949af"><gtr:id>44b2b5a25623eebfaee8f1247a7949af</gtr:id><gtr:otherNames>Wakerley BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>54637a557e6f33.76513049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86008A7F-233E-4D5C-9FCB-BB4538E0C271</gtr:id><gtr:title>Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fa71eb5bcb5dbba5a77cb5d30c89ec3"><gtr:id>9fa71eb5bcb5dbba5a77cb5d30c89ec3</gtr:id><gtr:otherNames>Oeckl P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>585d6ff0ba4d60.28154543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B887914-2F2F-4481-A50C-749BD88D99CC</gtr:id><gtr:title>Increased premorbid physical activity and amyotrophic lateral sclerosis: born to run rather than run to death, or a seductive myth?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12643_23_23447649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFE50C16-2CD7-4FCB-8050-F07653B41BD5</gtr:id><gtr:title>Advances in motor neurone disease.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c0ee7b319752e06e1099570139e53bb"><gtr:id>4c0ee7b319752e06e1099570139e53bb</gtr:id><gtr:otherNames>B?umer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>54637a56c2f6a7.37924389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2F57D98-20D1-4151-947A-DF7FC1EB6F3F</gtr:id><gtr:title>Apathy is associated with poor prognosis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f399b9670973f87351f0d29d1d23d747"><gtr:id>f399b9670973f87351f0d29d1d23d747</gtr:id><gtr:otherNames>Caga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>56d2c61a0a9ca8.76531836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>006FF608-F1F1-451A-92C6-B5FDD0A57E2E</gtr:id><gtr:title>Voxel-based MRI intensitometry reveals extent of cerebral white matter pathology in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430f102a251669a7bac6bb3dc08ce652"><gtr:id>430f102a251669a7bac6bb3dc08ce652</gtr:id><gtr:otherNames>Hartung V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54637a578dda41.00761259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E39F2A0-C14F-4822-BA64-F054545528BF</gtr:id><gtr:title>Identification of distinct circulating exosomes in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de5ee73dccccec3d9bb9e85c3b55fc4"><gtr:id>6de5ee73dccccec3d9bb9e85c3b55fc4</gtr:id><gtr:otherNames>Tomlinson PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>56d2c61ca075b2.56649411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E64B614A-FFFF-4553-B9C6-E0FAB024EAC4</gtr:id><gtr:title>Psychiatric disorders prior to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>58bc2d23494768.38709305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C56960B-CC21-4187-8A25-12084DBCE29E</gtr:id><gtr:title>Inflammation and neurovascular changes in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e7a2aaff095ddfd459f6f62ef8b765c"><gtr:id>3e7a2aaff095ddfd459f6f62ef8b765c</gtr:id><gtr:otherNames>Evans MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>pm_12643_23_23110760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17CABA4D-762A-44D3-9CEB-F5428A35DB95</gtr:id><gtr:title>The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6e261b5ce65b87737e7eb4b642351e4"><gtr:id>d6e261b5ce65b87737e7eb4b642351e4</gtr:id><gtr:otherNames>Gray E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d2c61d099133.64631758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CCA4B62-37F6-481F-A16C-8208DF257921</gtr:id><gtr:title>Focal precentral gyrus involvement in osmotic demyelination.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>5a6f2e37bb6c66.10109015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E8FC3BA-0263-47F1-A76B-1309151AFECD</gtr:id><gtr:title>Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77b34d0e3749b6ed66337c08edbfa8cc"><gtr:id>77b34d0e3749b6ed66337c08edbfa8cc</gtr:id><gtr:otherNames>Stagg CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>dQH4R1WBodx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0049A10E-B41B-4927-BCF9-87984CAF4D6A</gtr:id><gtr:title>Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7569f841febb9eac80c12095d94769d4"><gtr:id>7569f841febb9eac80c12095d94769d4</gtr:id><gtr:otherNames>Bowser B, Connor J, Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-0199590674</gtr:isbn><gtr:outcomeId>5463967b7e21d4.70801223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67A4CA45-1602-4B39-AA89-4A0F49CBAFA5</gtr:id><gtr:title>C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e81c1b62639e14af96c7a2fe30f14c54"><gtr:id>e81c1b62639e14af96c7a2fe30f14c54</gtr:id><gtr:otherNames>Dafinca R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>585d6fe9ec1632.43247738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E15E5C4-58DB-44D3-8702-E586A48AB6CF</gtr:id><gtr:title>Towards a TDP-43-Based Biomarker for ALS and FTLD.</gtr:title><gtr:parentPublicationTitle>Molecular neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50df457b1b750705477f70ae52f29e4a"><gtr:id>50df457b1b750705477f70ae52f29e4a</gtr:id><gtr:otherNames>Feneberg E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0893-7648</gtr:issn><gtr:outcomeId>5a995f2d479388.66675148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BCF9E48-AE34-4049-A108-36561AABC7D2</gtr:id><gtr:title>A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a31927906cffc4c4cbf31a0c8fd63195"><gtr:id>a31927906cffc4c4cbf31a0c8fd63195</gtr:id><gtr:otherNames>Thompson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58bc2d222d8c49.87232710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36B86AD5-9ABB-4B50-B009-2876C34DE635</gtr:id><gtr:title>Nutritional pathway for people with motor neurone disease.</gtr:title><gtr:parentPublicationTitle>British journal of community nursing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea51af6a4c671788ce1f87df08a609e5"><gtr:id>ea51af6a4c671788ce1f87df08a609e5</gtr:id><gtr:otherNames>Marsden R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-4753</gtr:issn><gtr:outcomeId>58bc2d241ed531.58393930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D461729A-3342-4D7D-8F2C-321FD358F365</gtr:id><gtr:title>Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de71aa6c2b9fb4dc7e18551b9ceb69e0"><gtr:id>de71aa6c2b9fb4dc7e18551b9ceb69e0</gtr:id><gtr:otherNames>Mattsson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61a3a5720.24312503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C76CFAE3-6D51-4369-8B6A-6CF0C9237038</gtr:id><gtr:title>Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/599b767c818053b41b61e52c89153c2a"><gtr:id>599b767c818053b41b61e52c89153c2a</gtr:id><gtr:otherNames>DiPALS Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>58bc2e0a8e0a12.56955746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6088AC3D-CEE1-4BC2-8539-504665A9A1B4</gtr:id><gtr:title>PET and SPECT in Neurology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-3-642-54307-4</gtr:isbn><gtr:outcomeId>5463954dcf39f6.66886927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13D2405A-B8A0-4650-AF26-12096F97FD3E</gtr:id><gtr:title>Unilateral leukonychia and hair depigmentation in multifocal motor neuropathy.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54638d6e659123.66204649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB93E5B3-172A-4923-989B-E2BA5D406A5A</gtr:id><gtr:title>Peer recommendations on how to improve clinical research, and Conference wrap-up.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd61e2545d67af6c3c96e8742a84f6b"><gtr:id>acd61e2545d67af6c3c96e8742a84f6b</gtr:id><gtr:otherNames>Chad DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51E55088-8D26-49DE-B171-231A8294843B</gtr:id><gtr:title>Assessment of the upper motor neuron in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44c9f74a31248e815d9cf1514d849d05"><gtr:id>44c9f74a31248e815d9cf1514d849d05</gtr:id><gtr:otherNames>Huynh W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1388-2457</gtr:issn><gtr:outcomeId>585d6fed77da05.25862570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B2531B5-E3B1-46BB-9B24-F018D90DEF98</gtr:id><gtr:title>Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>54638d6ddeecc5.45182372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F998C18-1D75-404E-89EB-178557246C28</gtr:id><gtr:title>Are neurofilaments heading for the ALS clinic?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61a66a911.69968598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EEAE4E0-FAC8-4A45-8CCC-310EB4FA5B86</gtr:id><gtr:title>Oxford Textbook of Clinical Neurology: Neuromuscular Disorders</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7ada31cae13180e506c25d1cec7fe06"><gtr:id>e7ada31cae13180e506c25d1cec7fe06</gtr:id><gtr:otherNames>Hilton-Jones D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978220221922969807223</gtr:isbn><gtr:outcomeId>54639702f209e5.53965952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C98AB166-0704-4F8A-93DC-1178EC804C2C</gtr:id><gtr:title>Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61ad661c7.20839185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D04EAB6-5A44-438D-983E-D5FA5FC42700</gtr:id><gtr:title>Swallowing and oropharyngeal dysphagia.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>56d2c61dd364d9.67080124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>250D216B-9A15-4FC3-B268-72EDE8EFFC44</gtr:id><gtr:title>The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d03ffb9b885afe6a58631746bc84369"><gtr:id>1d03ffb9b885afe6a58631746bc84369</gtr:id><gtr:otherNames>Proudfoot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58bc2d25360767.50037746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADCBC981-A8FB-4DBE-9DC3-3AF6F553DF06</gtr:id><gtr:title>Amyotrophic lateral sclerosis and cancer: a register-based study in Sweden.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/204e8f8efdacdd48a69a974f86cddff4"><gtr:id>204e8f8efdacdd48a69a974f86cddff4</gtr:id><gtr:otherNames>Fang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23527497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F864561A-9CE3-4286-BC38-A41CA39CA345</gtr:id><gtr:title>Magnetoencephalography.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d03ffb9b885afe6a58631746bc84369"><gtr:id>1d03ffb9b885afe6a58631746bc84369</gtr:id><gtr:otherNames>Proudfoot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>54638c5db542d8.33291098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708A8227-F82F-40A5-B170-5AF2E52E4926</gtr:id><gtr:title>What does imaging reveal about the pathology of amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Current neurology and neuroscience reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1528-4042</gtr:issn><gtr:outcomeId>56d2c61b9df969.67386966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0421DB4C-942E-4C50-953A-C30AD84CD83D</gtr:id><gtr:title>CSF neurofilament light chain reflects corticospinal tract degeneration in ALS.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>56d2c61c0b9335.87393765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB0EE2C2-D96E-4B7F-A905-8E96F8C27D35</gtr:id><gtr:title>Motor neuron disease: biomarker development for an expanding cerebral syndrome.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>58bc2d2304a224.51035996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>137038E6-C196-45D9-85E2-A53A5129B78A</gtr:id><gtr:title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a7bfa806ecaa3aa93efd2103aa2e758"><gtr:id>0a7bfa806ecaa3aa93efd2103aa2e758</gtr:id><gtr:otherNames>Cirulli ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>58bc2e0aec4364.37872323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2652CE2-ADE3-4697-A46B-A76C99DD8448</gtr:id><gtr:title>Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c6199fa2c8.41418506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA6C5114-CBEB-4A06-99E4-BA7118DE0D71</gtr:id><gtr:title>A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcdc79518e85ab24b449aa0dc5ef6366"><gtr:id>dcdc79518e85ab24b449aa0dc5ef6366</gtr:id><gtr:otherNames>M?ller HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61aa46d38.87946622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0FC85DD-1D40-47F9-9E2B-C8F7823FC66E</gtr:id><gtr:title>Progressive hemiparesis in a 75-year-old man.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4481ca1393b021ab022de27067a7e1d"><gtr:id>c4481ca1393b021ab022de27067a7e1d</gtr:id><gtr:otherNames>Fernandes PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>54638d6e13cea6.69436986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD3B8B4C-39B5-4FF4-8DF4-3078CAF85A35</gtr:id><gtr:title>Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb87f110bb4914af0973f4d8272af1b6"><gtr:id>bb87f110bb4914af0973f4d8272af1b6</gtr:id><gtr:otherNames>Balendra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>54637a5744ac89.35421928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>225A37D6-D018-4EC5-8556-DCE2C2B17529</gtr:id><gtr:title>Motor Neuron Disease in Adults</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6908988a9a607232738eabea8393d78"><gtr:id>d6908988a9a607232738eabea8393d78</gtr:id><gtr:otherNames>Turner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546395f698f5f9.53747457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70978389-CAA6-4F05-B9EA-2D5AB95939CE</gtr:id><gtr:title>Lou Gehrig and the ALS split hand.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466f54e223c3415ea467756cdb3ba04f"><gtr:id>466f54e223c3415ea467756cdb3ba04f</gtr:id><gtr:otherNames>Kiernan MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56d2c61b0c8ea3.78963908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0FC5B40-FDC3-4D99-9E29-B0CD5606EF79</gtr:id><gtr:title>A wider pathological network underlying breathlessness and respiratory failure in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bb470e3a0f1ce005a64b1ed4271296"><gtr:id>61bb470e3a0f1ce005a64b1ed4271296</gtr:id><gtr:otherNames>Pattinson KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58bc2d24736467.77273189</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K01014X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>